MEDNAX (MD) Misses Q3 EPS by 3c, Revenues Miss; Offers 4Q EPS Outlook Below Consensus
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/18/2026
- Wall Street indexes slip as oil prices rise, retail results awaited
- Trump threatens to bomb Oman over Iran stance
- Why this Wall Street strategist says the "trade is long gold"
- U.S. EV market shows signs of bottoming out: Bernstein
- Micron rises as White House presses Apple to avoid Chinese memory chips
- Wall Street indexes slip as oil prices rise, retail results awaited
- Micron rises as White House presses Apple to avoid Chinese memory chips
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Trump threatens to bomb Oman over Iran stance
- H.C. Wainwright Reiterates Buy Rating on Soluna (SLNH)
MEDNAX Reports Third Quarter GAAP EPS of $0.72; Adjusted EPS of $0.94
November 1, 2018 6:00 AM EDTAnnounces Initiation of Process to Sell MedData
FORT LAUDERDALE, Fla.--(BUSINESS WIRE)-- MEDNAX, Inc. (NYSE: MD), the national health solutions partner specializing in neonatology, anesthesiology, radiology, maternal-fetal medicine, other pediatric services, and management services, today reported earnings of $0.72 per diluted share for the three months ended September 30, 2018. On a non-GAAP basis, MEDNAX reported Adjusted EPS of $0.94.
For the 2018 third quarter, MEDNAX reported the following results:
Net revenue of $897 million; Net income of $66 million; and EBITDA of $141 million.... More